Torrent's Metformin Hydrochloride ANDA090014 Receives AP Status
Torrent's ANDA for Metformin Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.
Published: July 24, 2026
Updated: July 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / Oral Hypoglycemic
Company: Torrent Pharmaceuticals
Asset: Torrent
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Torrent Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's Abbreviated Approval of Torrent's Metformin Hydrochloride signifies increased competition in the diabetes treatment market. This could lead to market share shifts and pricing pressures on existing branded products, necessitating strategic responses from competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the launch date of Torrent's Metformin and any responses from competitors.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.